Pharmaceutical Industry

Gilead begins testing inhalable form of remdisivir for treating COVID-19

EU secures potential COVID-19 drugs from Roche, Germany’s Merck: source

Bellus stock drops 72% after highly anticipated drug disappoints in human trials

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

Aurora Cannabis to close facilities, lay off 700 workers in restructuring

Repare Therapeutics seeks to raise up to US$152-million in Nasdaq share offering

Lilly says COVID-19 treatment could be authorized for use as soon as September

Gilead signs deals with generic drugmakers to scale up COVID-19 drug supply

Canopy Growth says two top executives have left the cannabis firm

Bausch Health reports $152-million first-quarter loss due to COVID-19

Gilead working to make trial COVID-19 treatment remdesivir ‘accessible and affordable’

Eli Lilly lifts 2020 profit forecast; coronavirus fuels stockpiling of its medicines

Rush to beat COVID-19 is unprecedented in pharmaceutical industry, veteran executive says

Generic drug makers win EU approval to co-operate in coronavirus fight

Trump’s touting of unproven drug for COVID-19 has its own side effects

Europe ‘panicking’ over India’s pharmaceutical export curbs, industry group says

Gilead buys cancer drug developer Forty Seven for $4.9-billion

The U.S. has a problem with prescription-drug prices. Canada shouldn’t try to fix it

Place your bets: These are Bay Street’s highest and lowest rated stocks for 2020